Tom Henderson
- Lycera Corp., a University of Michigan spinoff developing drugs that target cancer and diseases of the immune system, has started human trials that could lead to the sale of the company next year.In December, the company finished a phase 1 U.S. Food and Drug Administration study that showed a compound with the working name of LYC-30937, which targets ulcerative colitis, is safe and well-tolerated by volunteers. A smaller phase 1b study began this year to assess absorption of the drug by
↧